- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07308860
Fraksjonell flytreserve mot angiografi for multivessel evaluering (FAME) 3 Utvidet
Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 3 Extended: En sammenligning av Fractional Flow Reserve-veiledet perkutan koronar intervensjon og koronar arterie bypass graft-kirurgi hos pasienter med multivessel koronar arteriesykdom
Coronary artery disease, or narrowing of the blood vessels that provide blood to the heart, is the most common cause of death in the United States and can be treated with either coronary bypass surgery or coronary stent placement. This study will evaluate outcomes, including death and quality of life, at 10 years in 1,500 patients with coronary disease who have already been randomized to either bypass surgery or stenting.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Coronary artery disease (CAD) remains the major cause of morbidity and mortality in adults in the United States. In patients with 3-vessel CAD not involving the left main coronary artery, percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) can improve outcomes. Older studies have shown that the more invasive option, CABG, significantly reduces mortality during long-term follow-up compared with PCI. However, these studies did not use contemporary methods to perform PCI, such as measuring an index called fractional flow reserve (FFR) with a coronary pressure wire or using current- generation drug-eluting stents (DES), both of which significantly improve outcomes after PCI. The Fractional flow reserve versus Angiography for Multivessel Evaluation (FAME) 3 trial randomized 1,500 patients to FFR-guided PCI with current generation DES or to CABG and found that at 5 years there was no significant difference in the composite of death, myocardial infarction (MI) or stroke between the two strategies. There was a reduction in MI in the CABG group. Longer-term follow-up is critical to determine if contemporary PCI results in similar survival as CABG. The primary aim of this project is to determine if 10-year mortality is different after FFR-guided PCI compared with CABG. Investigators will perform 10-year follow-up in the 1,500 patients randomized in the FAME 3 trial to determine if FFR-guided PCI is non-inferior to CABG with respect to mortality. Secondary aims include assessing quality of life and angina relief at 10 years in the two groups. Additionally, investigators will compare individual rates of secondary clinical outcomes including MI, stroke, and repeat revascularization at 10-year follow-up after PCI or CABG.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
California
-
Stanford, California, Forente stater, 94305
- Stanford University
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
This study will evaluate outcomes, including death and quality of life, at 10 years in 1,500 patients with coronary disease who have already been randomized to either bypass surgery or stenting.
Beskrivelse
Inclusion Criteria:
-
Age ≥ 21 years with angina and/or evidence of myocardial ischemia
-
Three vessel CAD, defined as ≥ 50% diameter stenosis by visual estimation in each of the three major epicardial vessels or major side branches, but not involving left main coronary artery, and amenable to revascularization by both PCI and CABG as determined by the Heart Team. Patients with a non-dominant right coronary artery may be included if only the left anterior descending artery (LAD) and left circumflex have
≥50% stenosis
-
Willing and able to provide informed, written consent
Exclusion Criteria:
- Requirement for other cardiac or non-cardiac surgical procedure (e.g., valve replacement, carotid revascularization), however a maze procedure or pulmonary vein isolation is allowed
- Cardiogenic shock and/or need for mechanical/pharmacologic hemodynamic support
- Recent STEMI (<5 days prior to randomization)
- Ongoing Non STEMI with biomarkers (cardiac troponin) still rising
- Known left ventricular ejection fraction <30%
- Life expectancy < 2 years
- Requiring renal replacement therapy
- Undergoing evaluation for organ transplantation
- Participation or planned participation in another clinical trial, except for observational registries
- Pregnancy
- Inability to take dual antiplatelet therapy or anticoagulation and single antiplatelet therapy for at least six months
- Previous CABG
- Left main disease requiring revascularization
- Extremely calcified or tortuous vessels precluding FFR measurement
- Any target lesion with in-stent drug-eluting stent restenosis
- More than one major epicardial vessel which is chronically occluded
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
FFR-guided PCI group
These patients have undergone fractional flow reserve-guided percutaneous coronary intervention |
Coronary stenting compared with coronary bypass surgery |
|
CABG group
These patients underwent coronary artery bypass grafting surgery |
Coronary artery bypass surgery |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Survival
Tidsramme: 10-year follow-up
|
The primary outcome is mortality or overall survival |
10-year follow-up
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Quality of life
Tidsramme: 10-year follow-up
|
Secondary aims include assessing quality of life at 10 years in the two groups utilizing the EQ-5D quality of life questionnaire. |
10-year follow-up
|
|
Angina Relief
Tidsramme: 10 year follow-up
|
Secondary aims include assessing angina status at 10 years in the two groups utilizing the Seattle Angina Questionnaire. |
10 year follow-up
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Major adverse cardiac events
Tidsramme: 10 year follow-up
|
Additionally, we will compare individual rates of secondary clinical outcomes including myocardial infarction (MI), stroke, and repeat revascularization and combinations of the above, including death and MI, and death, MI, or stroke at 10-year follow-up after PCI or CABG. |
10 year follow-up
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Smerte
- Nevrologiske manifestasjoner
- Cerebrovaskulære lidelser
- Hjernesykdommer
- Sykdommer i sentralnervesystemet
- Sykdommer i nervesystemet
- Vaskulære sykdommer
- Kardiovaskulære sykdommer
- Patologiske prosesser
- Hjertesykdommer
- Infarkt
- Nekrose
- Arteriosklerose
- Arterielle okklusive sykdommer
- Koronar sykdom
- Myokardiskemi
- Iskemi
- Brystsmerter
- Patologiske tilstander, tegn og symptomer
- Tegn og symptomer
- Slag
- Koronararteriesykdom
- Død
- Hjerteinfarkt
- Angina pectoris
Andre studie-ID-numre
- 83374
- 1R01HL179196-01 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .